Equilibrative Nucleoside Transporters during AKI

AKI 期间的平衡核苷转运蛋白

基本信息

项目摘要

Acute kidney injury (AKI) is among the leading cause of morbidity and mortality of hospitalized patients, and novel treatment options are urgently needed. The main goal of this proposal is to identify the functional contributions of adenosine transporters to renal protection from AKI. Moreover, we will utilize our findings in AKI to better understand the hypoxic adenosine response in acute or chronic states of lung injury and sickle cell disease (SCD). As such, our findings will address functional differences of extracellular adenosine during disease progression from acute injury into chronic disease states. Adenosine signaling plays an important role in tissue adaptation during hypoxia. Adenosine's effects are terminated via uptake from the extracellular towards the intracellular compartment through equilibrative nucleoside transporters (ENTs). Studies from our laboratory show that inhibition of ENTs enhances adenosine signaling during hypoxia and promotes protection from AKI. Studies in mice with genetic deletion of Enti or Ent2 identified a selective phenotype in Entl'^' mice, including higher adenosine levels, preserved kidney function, and attenuated inflammation. Subsequent studies of ENT inhibitor treatment in mice with deletion of individual adenosine receptors suggested the AD0RA2B adenosine receptor mediates kidney protection from AKI. Therefore, we hypothesize that inhibition or deletion of ENTI promotes kidney protection from ischemia by increasing extracellular adenosine and signaling events through the AD0RA2B. Four specific aims are proposed: Aim 1: Define the cell-specific contributions of ENTs during AKI, Aim 2: Study the transcriptional control of ENTs during ischemic AKI, Aim 3: Study the cell-specific functions of adenosine receptors in ENT-dependent kidney protection during ischemic AKI, and Aim 4: Study the role of the hypoxic adenosine response in AKI- driven lung injury. Together, these studies will provide novel insight into how the hypoxic adenosine response varies among different organ systems, which will help guide the use of adenosine-based therapeutics for kidney, lung and SCD associated disorders.
急性肾损伤(阿基)是住院患者发病率和死亡率的主要原因之一, 迫切需要新的治疗选择。本提案的主要目标是确定 腺苷转运蛋白对肾保护免受阿基的贡献。此外,我们将利用我们的研究结果, 阿基,以更好地了解急性或慢性肺损伤和镰状状态下的缺氧腺苷反应 细胞疾病(SCD)。因此,我们的研究结果将解决细胞外腺苷的功能差异, 从急性损伤到慢性疾病状态的疾病进展。腺苷信号传导在 在缺氧时组织适应中的作用。腺苷的作用是通过从细胞外的 通过平衡型核苷转运蛋白(ENTs)向细胞内区室转运。我们的研究 实验表明,在缺氧期间,抑制ENTs增强腺苷信号传导, 保护阿基。在具有Entl或Ent2的遗传缺失的小鼠中的研究鉴定了在小鼠中的选择性表型。 在小鼠中,包括更高的腺苷水平、保留的肾功能和减弱的炎症。 在缺失单个腺苷受体的小鼠中进行ENT抑制剂治疗的后续研究 表明AD0RA2B腺苷受体介导肾保护免受阿基。所以我们 假设ENTI抑制或缺失通过增加肾脏缺血保护作用, 细胞外腺苷和通过AD0RA2B的信号传导事件。提出了四个具体目标: 目的1:确定ENT在阿基中的细胞特异性作用,目的2:研究ENT的转录调控 目的3:研究腺苷受体在缺血性阿基中的细胞特异性功能, 目的4:研究缺氧腺苷反应在缺血性阿基中的作用。 驱动性肺损伤总之,这些研究将提供新的见解如何缺氧腺苷 不同器官系统的反应不同,这将有助于指导使用基于腺苷的 用于肾、肺和SCD相关病症的治疗剂。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Holger K. Eltzschig其他文献

Hypoxanthine-guanine phosphoribosyltransferase deficiency
次黄嘌呤鸟嘌呤磷酸核糖转移酶缺乏症
  • DOI:
    10.1007/978-3-540-29676-8_917
  • 发表时间:
    2020
  • 期刊:
  • 影响因子:
    0
  • 作者:
    D. Metze;V. F. Cury;Ricardo S. Gomez;L. Marco;Dror Robinson;Eitan Melamed;Alexander K. C. Leung;Jae;Yoichi Matsubara;Keiya Tada;S. Sancak;Ralf Paschke;S. Kupka;Stefan K. Plontke;H. Zenner;Gohar Azhar;Jeanne Y. Wei;Y. Kang;Katsuhiko Yoshizawa;Abraham Nyska;Graeme Jones;Kathy Triantafilou;P. Lepper;Johannes Bode;C. Kashtan;Klaus Schümann;Günter Weiss;C. Skerka;Christoph Licht;P. Zipfel;H. Cate;Mark Oette;D. Häussinger;Isabelle Ruel;P. Couture;Benoît Lamarche;S. Siegmund;Stephan L. Haas;Manfred V. Singer;Tobias Heintges;Ralf Kubitz;Andreas Erhardt;F. Lammert;J. Lorenzen;Hubert E. Blum;Darius Moradpour;Georg H. Merker;Matthias Wettstein;Mónica Guevara;Pere Ginés;H. Cate;Ulrich Heininger;Markus Pfister;M. Schmitt;A. Schinkel;D. Poldermans;Jeroen J. Bax;Heimo Mairbäurl;Peter Bärtsch;Georg H. Merker;Percy Chiu;R. Legro;William L. Nyhan;Sandeep S. Dave;Jürgen Kohlhase;A. Dielis;S. Harvey Mudd;Christian Simon;Oliver Schildgen;S. L. Sternak;G. Mlinarić‐Galinović;Eggert Stockfleth;I. Nindl;Inga Zerr;Mathias Bähr;N. Stankus;Katrin S. Lindenberg;G. Bernhard Landwehrmeyer;Jonas Denecke;S. Katsuragi;B. Grimbacher;C. Woellner;Steven Holland;Christian A. Koch;Michael T. Geraghty;Peter L. M. Jansen;Robert P. Whitehead;Edward M. Brown;Mei Bai;T. Martin;Joaquin Escribano;Victor M. Garca Nieto;Patrick T. S. Ma;Lucia K. Ma;Alexander K. C. Leung;Angelika F. Hahn;M. Nallegowda;Upinderpal Singh;M. Umapathi;Rakesh Kumar;R. Badolato;Benjamin Glaser;R. Schreiber;Daniel Landau;Goo Taeg Oh;C. Kallen;J. Topf;Patrick Murray;Jaime Tejedor;Manish Kumar Varshney;K. Suphapeetiporn;V. Shotelersuk;Bernd Hoppe;Albrecht Hesse;Geoffrey N. Hendy;David E. C. Cole;Charles R. Nolan;H. Shintaku;Hiroshi Ichinose;H. Mankin;G. Uwaifo;Bettina C. Reulecke;Werner Heppt;A. Cryer;Radoslav Tomić;Jesse Roman;J. Rémi;S. Noachtar;M. Nagase;Toshiro Fujita;Á. Cogolludo;Jason X.;Lewis J. Rubin;Manning R. Davis;T. Poduval;Saurabh Chatterjee;H. Gozu;Markus Eszlinger;R. Bircan;J. Lüblinghoff;Julia Lüblighoff;Roland Pfäffle;S. Zhao;Hui;J. Mogensen;R. Kebudi;Sezer Saglam;Michael A. Becker;J. Asplin;R. Gotshall;Hubert Scharnagl;Winfried März;John A. Sayer;Simon H.S. Pearce;James Paparello;P. Klemmer;Abhijit V. Kshirsagar;Patrick T. S. Ma;Lucia K. Ma;Marco Castori;Roswitha Siener;P. Habermehl;M. Knuf;Christoph Michalski;J. Kleeff;Annette Richter;Denis J. Headon;P. Overbeek;Alanna F. Bree;Hendrica Belge;Eva Riveira;Olivier Devuyst;Stefanie Weber;M. Moritz;J. Ayus;Simon H.S. Pearce;Michael P. Whyte;Masafumi Fukagawa;Motoko Tanaka;H. Tenenhouse;A. Gutenberg;Patrizio Caturegli;C. Oswalt;Pirooz Eghtesady;M. Suneja;Christie P. Thomas;H. Sasaki;T. Yukioka;Maurice van Steensel;R. Wu;Ping Wang;G. Feuerstein;Robert R. Ruffolo;H. Jinnah;James C. Harris;Holger K. Eltzschig;A. Grenz
  • 通讯作者:
    A. Grenz
Hypoxia signaling in human diseases and therapeutic targets
人类疾病中的缺氧信号通路及治疗靶点
  • DOI:
    10.1038/s12276-019-0235-1
  • 发表时间:
    2019-06-20
  • 期刊:
  • 影响因子:
    12.900
  • 作者:
    Jae W. Lee;Junsuk Ko;Cynthia Ju;Holger K. Eltzschig
  • 通讯作者:
    Holger K. Eltzschig
Images in Anesthesia: Detection of a defect pulmonary artery catheter balloon by transesophageal echocardiography
Intraoperative transesophageal echocardiography to assess septic coronary embolism.
术中经食管超声心动图评估脓毒性冠状动脉栓塞。
  • DOI:
    10.1097/00000542-200212000-00041
  • 发表时间:
    2002
  • 期刊:
  • 影响因子:
    8.8
  • 作者:
    Holger K. Eltzschig;Robert W. Lekowski;S. Shernan;S. Nedeljkovic;John G. Byrne;Raila Ehlers;S. Aranki
  • 通讯作者:
    S. Aranki
Netrin-1 attenuates acute kidney injury caused by ischemia
  • DOI:
    10.1016/j.jcrc.2010.08.026
  • 发表时间:
    2010-12-01
  • 期刊:
  • 影响因子:
  • 作者:
    Julee Hong Dalton;Jessica Bauerle;Leslie Cabrera;Jae-Hwan Kim;Carol Aherne;Almut Grenz;Holger K. Eltzschig
  • 通讯作者:
    Holger K. Eltzschig

Holger K. Eltzschig的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Holger K. Eltzschig', 18)}}的其他基金

Functional Role of HIF-PHDs in ARDS
HIF-PHD 在 ARDS 中的功能作用
  • 批准号:
    10718267
  • 财政年份:
    2023
  • 资助金额:
    $ 51.69万
  • 项目类别:
Circadian Rhythm as a Therapeutic Target for Perioperative Cardioprotection
昼夜节律作为围手术期心脏保护的治疗目标
  • 批准号:
    10659089
  • 财政年份:
    2023
  • 资助金额:
    $ 51.69万
  • 项目类别:
Research Training of Anesthesiology Physician-Scientists
麻醉医师科学家的研究培训
  • 批准号:
    10618804
  • 财政年份:
    2022
  • 资助金额:
    $ 51.69万
  • 项目类别:
Research Training of Anesthesiology Physician-Scientists
麻醉医师科学家的研究培训
  • 批准号:
    10333808
  • 财政年份:
    2022
  • 资助金额:
    $ 51.69万
  • 项目类别:
Targeting MicroRNA miR-122 for the Treatment of Perioperative Liver Injury
靶向 MicroRNA miR-122 治疗围手术期肝损伤
  • 批准号:
    10598586
  • 财政年份:
    2020
  • 资助金额:
    $ 51.69万
  • 项目类别:
Targeting MicroRNA miR-122 for the Treatment of Perioperative Liver Injury
靶向 MicroRNA miR-122 治疗围手术期肝损伤
  • 批准号:
    10366015
  • 财政年份:
    2020
  • 资助金额:
    $ 51.69万
  • 项目类别:
microRNA miR-147 Dampens Alveolar Epithelial Inflammation During ARDS
microRNA miR-147 抑制 ARDS 期间的肺泡上皮炎症
  • 批准号:
    10316251
  • 财政年份:
    2020
  • 资助金额:
    $ 51.69万
  • 项目类别:
microRNA miR-147 Dampens Alveolar Epithelial Inflammation During ARDS
microRNA miR-147 抑制 ARDS 期间的肺泡上皮炎症
  • 批准号:
    10535454
  • 财政年份:
    2020
  • 资助金额:
    $ 51.69万
  • 项目类别:
Targeting MicroRNA miR-122 for the Treatment of Perioperative Liver Injury
靶向 MicroRNA miR-122 治疗围手术期肝损伤
  • 批准号:
    9980672
  • 财政年份:
    2020
  • 资助金额:
    $ 51.69万
  • 项目类别:
Targeting MicroRNA miR-122 for the Treatment of Perioperative Liver Injury
靶向 MicroRNA miR-122 治疗围手术期肝损伤
  • 批准号:
    10162584
  • 财政年份:
    2020
  • 资助金额:
    $ 51.69万
  • 项目类别:

相似海外基金

Combinatorial cytokine-coated macrophages for targeted immunomodulation in acute lung injury
组合细胞因子包被的巨噬细胞用于急性肺损伤的靶向免疫调节
  • 批准号:
    10648387
  • 财政年份:
    2023
  • 资助金额:
    $ 51.69万
  • 项目类别:
Lung epithelial cell-derived C3 in acute lung injury
肺上皮细胞衍生的 C3 在急性肺损伤中的作用
  • 批准号:
    10720687
  • 财政年份:
    2023
  • 资助金额:
    $ 51.69万
  • 项目类别:
Examining the role of TRMT1 and tRNA methylation in acute lung injury and ARDS
检查 TRMT1 和 tRNA 甲基化在急性肺损伤和 ARDS 中的作用
  • 批准号:
    10719249
  • 财政年份:
    2023
  • 资助金额:
    $ 51.69万
  • 项目类别:
Inducible HMGB1 antagonist for viral-induced acute lung injury.
诱导型 HMGB1 拮抗剂,用于治疗病毒引起的急性肺损伤。
  • 批准号:
    10591804
  • 财政年份:
    2023
  • 资助金额:
    $ 51.69万
  • 项目类别:
MAP2K1 AND MAP2K2 IN ACUTE LUNG INJURY AND RESOLUTION
MAP2K1 和 MAP2K2 在急性肺损伤中的作用及缓解
  • 批准号:
    10741574
  • 财政年份:
    2023
  • 资助金额:
    $ 51.69万
  • 项目类别:
Development of a new treatment for COVID-19-related acute lung injury targeting the microbiota-derived peptide corisin
针对微生物群衍生肽 corisin 开发治疗 COVID-19 相关急性肺损伤的新疗法
  • 批准号:
    23K07651
  • 财政年份:
    2023
  • 资助金额:
    $ 51.69万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Probing immunovascular mechanobiology in pneumonia-associated acute lung injury at the single capillary level
在单毛细血管水平探讨肺炎相关急性肺损伤的免疫血管力学生物学
  • 批准号:
    10679944
  • 财政年份:
    2023
  • 资助金额:
    $ 51.69万
  • 项目类别:
The amyloid precursor protein protects against acute lung injury
淀粉样前体蛋白可预防急性肺损伤
  • 批准号:
    10575258
  • 财政年份:
    2023
  • 资助金额:
    $ 51.69万
  • 项目类别:
Role of macrophages and miRNA in regulating lung macrophage polarization and lung pathogenesis during respiratory virus-induced acute lung injury in normal and diabetic Syrian hamsters.
正常和糖尿病叙利亚仓鼠呼吸道病毒引起的急性肺损伤期间巨噬细胞和 miRNA 在调节肺巨噬细胞极化和肺部发病机制中的作用。
  • 批准号:
    10701207
  • 财政年份:
    2023
  • 资助金额:
    $ 51.69万
  • 项目类别:
Roles of N-glycans on neutrophil beta2 integrins in progression of acute lung injury
N-聚糖对中性粒细胞β2整合素在急性肺损伤进展中的作用
  • 批准号:
    10837431
  • 财政年份:
    2023
  • 资助金额:
    $ 51.69万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了